[go: up one dir, main page]

BRPI0416739A - derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia - Google Patents

derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia

Info

Publication number
BRPI0416739A
BRPI0416739A BRPI0416739-2A BRPI0416739A BRPI0416739A BR PI0416739 A BRPI0416739 A BR PI0416739A BR PI0416739 A BRPI0416739 A BR PI0416739A BR PI0416739 A BRPI0416739 A BR PI0416739A
Authority
BR
Brazil
Prior art keywords
treatment
schizophrenia
related compounds
indane derivatives
heterocyclic substituted
Prior art date
Application number
BRPI0416739-2A
Other languages
English (en)
Inventor
James Michael Graham
Brian Edward Kornberger
Sham Shridhar Nikam
Dejian Xie
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34811295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0416739A publication Critical patent/BRPI0416739A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE INDANO SUBSTITUìDO HETEROCìCLICO E COMPOSTOS AFINS PARA O TRATAMENTO DE ESQUIZOFRENIA". A presente invenção refere-se a compostos da fórmula 1 onde J, M, G, m, X, R¬ 1¬, R¬ 2¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬, R¬ 8¬, R¬ 9¬, Y, n, z, e R¬ 11¬ são como definidos no relatório descritivo, composições farmacêuticas contendo os mesmos e seu uso no tratamento de distúrbios do sistema nervoso central e outros distúrbios.
BRPI0416739-2A 2003-12-08 2004-11-26 derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia BRPI0416739A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52785203P 2003-12-08 2003-12-08
US53109603P 2003-12-19 2003-12-19
PCT/IB2004/003898 WO2005056540A1 (en) 2003-12-08 2004-11-26 Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BRPI0416739A true BRPI0416739A (pt) 2007-01-16

Family

ID=34811295

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416739-2A BRPI0416739A (pt) 2003-12-08 2004-11-26 derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia

Country Status (12)

Country Link
US (1) US20050282819A1 (pt)
EP (1) EP1697334A1 (pt)
JP (1) JP2007513197A (pt)
AR (1) AR047325A1 (pt)
BR (1) BRPI0416739A (pt)
CA (1) CA2548447A1 (pt)
NL (1) NL1027680C2 (pt)
PA (1) PA8619301A1 (pt)
PE (1) PE20050862A1 (pt)
TW (1) TW200524922A (pt)
UY (1) UY28656A1 (pt)
WO (1) WO2005056540A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2007076601A1 (en) * 2006-01-03 2007-07-12 Clera Inc. Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof
TW200804347A (en) * 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
KR20090040352A (ko) 2006-07-31 2009-04-23 얀센 파마슈티카 엔.브이. 유로텐신 ⅱ 수용체 길항제
WO2010017105A1 (en) * 2008-08-02 2010-02-11 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
IL146564A0 (en) * 1999-05-24 2002-07-25 Mitsubishi Pharma Corp Phenoxypropylamine derivatives and pharmaceutical compositions containing the same
AU7547100A (en) * 1999-09-09 2001-04-10 Egis Gyogyszergyar Rt. Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
BR0314393A (pt) * 2002-09-17 2005-07-19 Warner Lambert Co Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
MXPA05002003A (es) * 2002-09-26 2005-08-03 Warner Lambert Co Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia.

Also Published As

Publication number Publication date
UY28656A1 (es) 2005-07-29
NL1027680C2 (nl) 2005-11-30
JP2007513197A (ja) 2007-05-24
US20050282819A1 (en) 2005-12-22
PE20050862A1 (es) 2005-12-17
AR047325A1 (es) 2006-01-18
CA2548447A1 (en) 2005-06-23
TW200524922A (en) 2005-08-01
NL1027680A1 (nl) 2005-06-09
EP1697334A1 (en) 2006-09-06
WO2005056540A1 (en) 2005-06-23
PA8619301A1 (es) 2005-11-25

Similar Documents

Publication Publication Date Title
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR0314113A (pt) Derivados de amino propanol
BRPI0417571A (pt) 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0413151A (pt) derivados de amino propanol
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BRPI0511874A (pt) derivados da pirrolopiridina
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BRPI0416739A (pt) derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.